Faslodex [fulvestrant] Observations During Regular Use by Advanced Mammacarcinoma Patients

Trial Profile

Faslodex [fulvestrant] Observations During Regular Use by Advanced Mammacarcinoma Patients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 May 2009

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms FORUM
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 May 2009 Planned end date (1 Dec 2009) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Oct 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top